Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SBRT Sequential Surufatinib and Camrelizumab for Biliary Tract Cancer
NCT06199882Phase 2Suspended
- Sponsor
- Zhejiang Cancer Hospital
- Start
- Feb 2024
- Primary completion
- Jun 2025
- Modality
- Fragment-Derived Small Molecules, Immune Checkpoint Inhibitors, Allosteric Modulators
- Countries
- 1
01
Overview
A Phase 2 trial of surufatinib, camrelizumab in biliary tract cancer (BTC), sponsored by Zhejiang Cancer Hospital. Started Feb 2024; status: suspended.
02
Drugs
surufatinibcamrelizumab
03
Conditions
biliary tract cancer (BTC)
Beyond the preview
Go deeper on NCT06199882.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06199882.